S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$8.78
+0.27 (+3.17 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.37
Now: $8.78
$8.94
50-Day Range
$7.04
MA: $7.94
$9.23
52-Week Range
$4.53
Now: $8.78
$19.11
Volume751,299 shs
Average Volume340,000 shs
Market Capitalization$500.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Accelerate Diagnostics logo

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

268th out of 1,922 stocks

Analytical Instruments Industry

6th out of 29 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100
Employees275

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.30 million
Book Value($0.14) per share

Profitability

Net Income$-84,310,000.00
Net Margins-697.50%

Miscellaneous

Market Cap$500.72 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$8.78
+0.27 (+3.17 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXDX stock has decreased by 17.2% and is now trading at $8.78.
View which stocks have been most impacted by COVID-19
.

Is Accelerate Diagnostics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Accelerate Diagnostics?

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Accelerate Diagnostics
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Tuesday, November, 10th. The medical research company reported ($0.33) EPS for the quarter, meeting analysts' consensus estimates of ($0.33). The medical research company had revenue of $3.59 million for the quarter, compared to analyst estimates of $3.37 million.
View Accelerate Diagnostics' earnings history
.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.1-3.1 million, compared to the consensus revenue estimate of $4.41 million.

What price target have analysts set for AXDX?

3 equities research analysts have issued 1 year target prices for Accelerate Diagnostics' shares. Their forecasts range from $15.00 to $20.00. On average, they expect Accelerate Diagnostics' share price to reach $17.50 in the next year. This suggests a possible upside of 99.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view Wall Street analyst' top-rated stocks.

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), MagnaChip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Jack Phillips, CEO, Pres & Director (Age 55, Pay $289.43k)
  • Mr. Steve Reichling, CFO, Chief Accounting Officer & Sec. (Age 43, Pay $340k)
  • Mr. Lawrence Mehren, Advisor (Age 55, Pay $500k)
  • Mr. Ron Price, Chief Commercial Officer of Americas (Age 57, Pay $240k)
  • Laura Pierson, Investor Relations Officer
  • Mr. Michael Bridge, Sr. VP & Gen. Counsel
  • Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
  • Ms. Constance Bridges, Sr. VP and Head of Regulatory & Quality
  • Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
  • Ms. Laura Costa, Sr. VP & Head of Global Customer Support

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Thompson Investment Management Inc. (0.11%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Romney Humphries and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics
.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc.. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $8.78.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $500.72 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 275 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.